Dyax, Kadmon deal

Dyax granted Kadmon exclusive, worldwide development and commercialization rights for DX-2400. Dyax will receive an undisclosed upfront payment and is eligible for milestones, plus tiered royalties up to a double-digit rate. DX-2400 is a protease inhibitor that inhibits matrix metalloproteinase 14 (MMP14). ...